Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01816074 · ClinicalTrials.gov registry record · Phase 4
Sequencing Treatments for Mothers With ADHD and Their At - Risk Children
A Phase 4 study, sponsored by Seattle Children's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 53
- Enrollment target
NCT01816074 is a Phase 4 study that has completed, run by Seattle Children's Hospital. The registered enrollment target is 53 participants.
The verdict
NCT01816074, a Phase 4 study, has completed, sponsored by Seattle Children's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 53 participants
- Enrollment target
Study Summary
We hypothesize that successfully treating maternal Attention Deficit Hyperactivity Disorder (ADHD) will have a beneficial effect that extends to the child. We believe that multi-component interventions combining maternal stimulant medication, Lisdexamfetamine (LDX), and Behavioral Parent Training (BPT) will improve parenting, maternal, and child outcomes. In terms of improved parenting, we hypothesize that some mothers may respond well to LDX or BPT alone and therefore may not require multi-modal treatment, whereas others may benefit most from multi-modal treatment
Interventions
- DRUG Vyvanse (lisdexamphetamine)
- BEHAVIORAL Behavior Parent Training
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2012-10 |
| Est. Completion | 2017-05-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01816074
The ClinicalTrials.gov registry entry for NCT01816074 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Children's Hospital, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vyvanse (lisdexamphetamine) is the first listed.
NCT01816074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01816074 about?
NCT01816074 is a clinical study titled "Sequencing Treatments for Mothers With ADHD and Their At - Risk Children". We hypothesize that successfully treating maternal Attention Deficit Hyperactivity Disorder (ADHD) will have a beneficial effect that extends to the child. We believe that multi-component interventions combining maternal stimulant medication, Lisdexamfetamine (LDX), and Behavioral Parent Training (B...
What is the current status of trial NCT01816074?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 53 participants. The study started on 2012-10. Estimated completion is 2017-05-01.
What interventions are being tested in trial NCT01816074?
The interventions under investigation include: Vyvanse (lisdexamphetamine) (DRUG), Behavior Parent Training (BEHAVIORAL).
Who is sponsoring clinical trial NCT01816074?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.